Peto 2021(c) [C ‐ Lab tested].

Study characteristics
Patient Sampling	Comparative study of 7 Ag tests (no product codes reported); Peto 2021(c) [A ‐ Lab tested] reports full study characteristics and QUADAS
Patient characteristics and setting	Comparative study of 7 Ag tests (no product codes reported); Peto 2021(c) [A ‐ Lab tested] reports full study characteristics and QUADAS
Index tests	Comparative study of 4 Ag tests (no product codes reported); Peto 2021(c) [C ‐ Lab tested] data relate to test [C], see additional entries for other assays Test name: [A] Innova SARS‐CoV‐2 Antigen Rapid Qualitative Test [B] Panbio COVID‐19 Ag Rapid Test Device [C] Coronavirus Ag Rapid Test Cassette [D] Anhui Deepblue Medical Technology COVID‐19 Manufacturer: [A] Innova Medical Group [B] Abbott [C] Zhejiang Orient Gene Biotech [D] Deepblue Antibody: not stated Ag target: not stated Test method: not stated Samples used: combined AN and OP swabs (1 stored as a dry swab and 1 swab placed in VTM; swabs were self‐collected Transport media: dry swab Sample storage: (1) immediate on‐site testing by HCW (2) transport to PHE; tested within 24 h of collection Test operator: (1) Immediate testing by HCW (assay [A]) (2) laboratory scientist tested at PHE (assay [A] to [D]) Definition of test positivity: visual line; as per manufacturer IFU An invalid kit result, or a kit failure was recorded when an operator did not see a control line on the device within a defined time period Blinding reported: yes for on‐site HCW testing; lab scientists reported as unaware of clinical information from the study participants Timing of samples: not stated
Target condition and reference standard(s)	Comparative study of 7 Ag tests (no product codes reported); Peto 2021(c) [A ‐ Lab tested] reports full study characteristics and QUADAS
Flow and timing	Comparative study of 7 Ag tests (no product codes reported); Peto 2021(c) [A ‐ Lab tested] reports full study characteristics and QUADAS
Comparative
Notes